EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)

Tomohiro Ishii, Kenichi Kashimada, Naoko Amano, Kei Takasawa, Akari Nakamura-Utsunomiya, Shuichi Yatsuga, Tokuo Mukai, Shinobu Ida, Mitsuhisa Isobe, Masaru Fukushi, Hiroyuki Satoh, Kaoru Yoshino und 3 weitere

Clinical Pediatric Endocrinology · 2022 · 31 (3) · 116-143

DOI: 10.1297/cpe.2022-0009 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Pediatric Endocrinology, 2022. Verfasst von Tomohiro Ishii und 14 weiteren Autor:innen. Beteiligte Einrichtung: Differences of Sex Development (DSD) and Adrenal Disorders Committee, Japanese Society for Pediatric Endocrinology. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 219 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Congenital adrenal hyperplasia is a category of disorders characterized by impaired adrenocortical steroidogenesis. The most frequent disorder of congenital adrenal hyperplasia is 21-hydroxylase deficiency, which is caused by pathogenic variants of CAY21A2 and is prevalent between 1 in 18,000 and 20,000 in Japan. The clinical guidelines for 21-hydroxylase deficiency in Japan have been revised twice since a diagnostic handbook in Japan was published in 1989. On behalf of the Japanese Society for Pediatric Endocrinology, the Japanese Society for Mass Screening, the Japanese Society for Urology, and the Japan Endocrine Society, the working committee updated the guidelines for the diagnosis and treatment of 21-hydroxylase deficiency published in 2014, based on recent evidence and knowledge related to this disorder. The recommendations in the updated guidelines can be applied in clinical practice considering the risks and benefits to each patient.

Schlagwörter

Stichwörter der Autor:innen

21-hydroxylase deficiencycongenital adrenal hyperplasiaguidelineneonatal mass screening

Autor:innen und Institutionen

  • Differences of Sex Development (DSD) and Adrenal Disorders Committee, Japanese Society for Pediatric Endocrinology.
  • Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
  • Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Committee on Mass Screening, Japanese Society for Pediatric Endocrinology.
  • Department of Pediatrics, Saitama City Hospital, Saitama, Japan.
  • Department of Pediatrics, Hiroshima Prefectural Hospital, Hiroshima, Japan.

Zitieren

APA

Ishii, T., Kashimada, K., Amano, N., Takasawa, K., Nakamura-Utsunomiya, A., Yatsuga, S., Mukai, T., Ida, S., Isobe, M., Fukushi, M., Satoh, H., Yoshino, K., Otsuki, M., Katabami, T., & Tajima, T. (2022). Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision). Clinical Pediatric Endocrinology, 31(3), 116-143. https://doi.org/10.1297/cpe.2022-0009

Vancouver

Ishii T, Kashimada K, Amano N, Takasawa K, Nakamura-Utsunomiya A, Yatsuga S, et al. Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision). Clinical Pediatric Endocrinology. 2022;31(3):116-143. doi:10.1297/cpe.2022-0009

BibTeX
@article{Ishii2022,
  author = {Ishii, Tomohiro and Kashimada, Kenichi and Amano, Naoko and Takasawa, Kei and Nakamura-Utsunomiya, Akari and Yatsuga, Shuichi and Mukai, Tokuo and Ida, Shinobu and Isobe, Mitsuhisa and Fukushi, Masaru and Satoh, Hiroyuki and Yoshino, Kaoru and Otsuki, Michio and Katabami, Takuyuki and Tajima, Toshihiro},
  title = {Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)},
  journal = {Clinical Pediatric Endocrinology},
  year = {2022},
  volume = {31},
  number = {3},
  pages = {116--143},
  doi = {10.1297/cpe.2022-0009}
}
Kostenlos starten →